These medications (including semaglutide, dulaglutide, and liraglutide) are typically considered when: Metformin and other oral medications have not achieved adequate glycaemic control The patient has a BMI 35 kg/m (or lower thresholds, typically by around 2.5 kg/m, for people of certain ethnic backgrounds including South Asian) Weight loss would benefit other obesity-related comorbidities Insulin therapy is being considered but would have significant occupational implications or weight gain is a concern Continuation criteria apply: for example, treatment should reduce HbA1c by at least 11 mmol/mol (1.0%) and weight by at least 3% at 6 months to be continued
Dong P, Maddali MV, Srimani JK, Thlot F, Nevins JR, Mathey-Prevot B, et al
On the other hand, vitamin E oxidized metabolite -tocopheryl quinone (-TQ) has been reported to be an emerging plasma biomarker of lipotoxicity in subjects with fatty liver [48]
Laparoscopic Collis gastroplasty and Nissen fundoplication
Your work is too important to be compromised by subpar materials
HCCH and JNs present address is: University of Copenhagen, Copenhagen, Denmark
